BiotechTube
Home/PharmaSGP/Dr. Anna Schmidt
DA

Dr. Anna Schmidt

Chief Scientific Officer

PharmaSGP

Therapeutic Areas

NeurologyRare DiseasesCentral Nervous System

PharmaSGP Pipeline

DrugIndicationPhase
PSG-101Parkinson's Disease (Motor Fluctuations)Phase 2
PSG-102Focal Onset Seizures (Epilepsy)Phase 2
PSG-103Rare Genetic Movement DisorderPhase 1/2
PSG-201Neuropathic PainPhase 1
PSG-301Treatment-resistant DepressionPreclinical
PSG-401Pediatric Neurological DisorderPreclinical

Leadership Team at PharmaSGP

DM
Dr. Markus Fischer
Chief Executive Officer
TW
Thomas Weber
Chief Financial Officer
PD
Prof. Dr. Klaus Wagner
Chairman of the Supervisory Board
DS
Dr. Sabine Hoffmann
Head of Clinical Development
MB
Michael Bauer
Head of Business Development
DE
Dr. Elena Petrova
Head of Research
PD
Prof. Dr. Hans Müller
Scientific Advisory Board Member
DL
Dr. Laura Moretti
Scientific Advisory Board Member
JK
Johannes Klein
Supervisory Board Member
DF
Dr. Franz Becker
Supervisory Board Member
View full PharmaSGP profile